Literature DB >> 20886661

The glycolipid sulfatide protects insulin-producing cells against cytokine-induced apoptosis, a possible role in diabetes.

A Roeske-Nielsen1, L T Dalgaard, J-E Månsson, K Buschard.   

Abstract

AIMS/HYPOTHESIS: Cytokine-induced apoptosis is recognised as a major cause of the decline in β-cell mass that ultimately leads to type 1 diabetes mellitus. Interleukin-1β, interferon-γ and tumour necrosis factor-α in conjunction initiate a series of events that lead to β-cell apoptosis; important among these is NO production. The glycosphingolipid sulfatide is present in β-cells in the secretory granules in varying amounts and is secreted together with insulin. We now investigate whether sulfatide is able to protect insulin-producing cells against the pro-apoptotic effect of interleukin-1β, interferon-γ and tumour necrosis factor-α.
METHODS: INS-1E cells and genuine rat islets were incubated for 24 h exposed to interleukin-1β, interferon-γ and tumour necrosis factor-α with or without sulfatide. The production of NO was monitored and the number of apoptotic cells was determined using terminal deoxynucleotidyl transferase-mediated dUTP Nick-End labelling and caspase-3/7 activity assays. In addition, the amount of iNOS mRNA was determined using real-time quantitative polymerase chain reaction.
RESULTS: Cytokine-induced apoptosis was reduced to 27% of cytokine-treated controls with 30 µmol/L sulfatide treatment (p < 0.01). Likewise, sulfatide in concentrations of 3-30 µmol/L decreased NO production in a dose-dependent manner to 19-40% of cytokine-treated controls (overall p = 0.0007). The level of iNOS mRNA after cytokine exposure was reduced to 55% of cytokine-treated controls with 30 µmol/L of sulfatide. CONCLUSIONS/
INTERPRETATION: In the present study, we report the ability of sulfatide to significantly reduce apoptosis, cellular leakage and NO production in insulin-producing cells. Data suggest this is not due to induction of β-cell rest. Our findings indicate a possible implication for sulfatide in the pathogenesis of diabetes.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886661     DOI: 10.1002/dmrr.1130

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

Review 1.  Role of sulfatide in normal and pathological cells and tissues.

Authors:  Tadanobu Takahashi; Takashi Suzuki
Journal:  J Lipid Res       Date:  2012-05-22       Impact factor: 5.922

2.  A model of metformin mitochondrial metabolism in metachromatic leukodystrophy: first description of human Schwann cells transfected with CRISPR-Cas9.

Authors:  Nayibe Tatiana Sanchez-Álvarez; Paula Katherine Bautista-Niño; Juanita Trejos-Suárez; Norma Cecilia Serrano-Díaz
Journal:  Open Biol       Date:  2022-07-06       Impact factor: 7.124

Review 3.  Sphingolipids in obesity, type 2 diabetes, and metabolic disease.

Authors:  S B Russo; J S Ross; L A Cowart
Journal:  Handb Exp Pharmacol       Date:  2013

4.  Self-glycolipids modulate dendritic cells changing the cytokine profiles of committed autoreactive T cells.

Authors:  Karsten Buschard; Jan-Eric Månsson; Bart O Roep; Tatjana Nikolic
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

5.  Apoptosis of non-parasitised red blood cells in Plasmodium yoelii malaria.

Authors:  Paulo Renato Rivas Totino; Raquel Alves Pinna; Ana Cecilia Amado Xavier de Oliveira; Dalma Maria Banic; Cláudio Tadeu Daniel-Ribeiro; Maria de Fátima Ferreira-da-Cruz
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-09       Impact factor: 2.743

Review 6.  Sphingolipids in Type 1 Diabetes: Focus on Beta-Cells.

Authors:  Ewa Gurgul-Convey
Journal:  Cells       Date:  2020-08-04       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.